Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma
SYDNEY, Nov. 18, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a summary of new paxalisib data presented at the Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from...
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
SYDNEY, Aug. 22, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc inOcto...
Board Review of Business Operations and Governance
SYDNEY, Aug. 14, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appo...
Progress Update on Cantrixil(TM) (TRXE-002-1) Development
SYDNEY, Aug. 7, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Phase I Clinical Trial in Ovarian Cancer Pro...
Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure
- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC position Novogen for success in these activities - Dr David Brown, Chief Scientific Officer...
Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program
SYDNEY, March 6, 2017 /PRNewswire/ -- * Grant is provided under Cooperative Research Centre Project (CRC-P) scheme and provides up toA$3 million in cash over three years * Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new ...
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has fully-acquired Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. The transaction includes ...
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma
SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialise GDC-0084, a small ...
Conversion of Convertible Notes
SYDNEY, Sept. 14, 2016 /PRNewswire/ -- On 19 April 2013, the shareholders of Novogen Limited approved the issue of 60,000,000 convertible securities, with a face value of$1.5M, to the former securities holders of Triaxial Pharmaceuticals Pty Ltd. The conversions of the convertible notes are cont...
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer
SYDNEY, Sept. 12, 2016 /PRNewswire/ -- * Cantrixil (TRX-E-002-1) is Novogen's lead development candidate, and is being developed as an intraperitoneal therapy for patients with ovarian cancer * Investigational New Drug (IND) application is the key regulatory filing to initiate clinical trial...
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
SYDNEY, Aug. 11, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002...
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant
SYDNEY, June 14, 2016 /PRNewswire/ -- US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted inAustralia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507). Novogen North Am...
Novogen Provides Update On Development Of Cantrixil
SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian canc...
Novogen Receives R&D Tax Incentive Cash Refund
SYDNEY, March 17, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of$2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending30 June 2015. This wi...
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant
SYDNEY, Feb. 19, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted inAustralia. This patent provides full prot...
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
SYDNEY, Feb. 5, 2016 /PRNewswire/ -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, MrJohn O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James G...
Novogen Appoints Dr James Garner as Chief Executive Officer
SYDNEY, Dec. 10, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of D...
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial
SYDNEY, Nov. 24, 2015 /PRNewswire/ -- * Novogen engages Novotech as CRO for upcoming Phase 1 clinical study * Cantrixil Phase 1 clinical trial to be conducted in patients with refractory/recurrent peritoneal malignancies with malignant ascites, including ovarian cancer US-Australian drug dis...
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia
SYDNEY, Nov. 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia. According to Novogen North Ameri...
Novogen Applies for Long-term Options Listing
SYDNEY, Sept. 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today announced that it will apply for the listing of the Long-Term Options on ASX and anticipates that this request will be granted within the next week. An Appendix 3B has been ...
